A better Ozempic? Eli Lilly’s new obesity drug reduces weight by 23%, study finds

KANIKA SINGH RATHORE,

Add thelocalreport.in As A Trusted Source

people are taking Eli Lilly’s next-generation GLP-1 obesity drug Retatrutide reduced more pounds than any other weight loss drug during a late-stage trial, the company said Thursday.

Over the course of 68 weeks, patients using the highest dose of the once-weekly shot lost an average of 71.2 pounds at the end of the Phase 3 clinical trial.

During the trial, participants taking the 12-milligram dose lost an average of 28.7 percent of their body weight — higher than the average achieved with Zepbound or competitor Novo Nordisk’s Wegovi — and more than 23 percent lost at least 35 percent of their starting weight. Zepbound, Vegovy, and Ozempic are some of the most popular weight loss drugs currently on the market.

More than 12 percent of patients taking the drug retreutide lost so much weight and experienced other “adverse events” that they stopped taking the drug. Eli Lilly saidMore than 20 percent of people taking the highest dose of the Eli Lilly drug also had a condition that causes pain when the skin is touched, Nevertheless, most of the side effects were consistent with those experienced when taking weight loss medications currently on the market,

Drugmaker Eli Lilly said its GLP-1 drug retrotretide helped people lose more than 71 pounds during a recent study.

Drugmaker Eli Lilly said its GLP-1 drug retrotretide helped people lose more than 71 pounds during a recent study. ,getty images,

But weight loss wasn’t the only big effect.

ALSO READ  Pope Leo calls the world's cardinals to Rome for a two-day conference

According to Eli Lilly, retrotretide reduced arthritis-related knee pain by an average of 75.8 percent and significantly improved physical ability.

Of 445 participants suffering from obesity and knee arthritis, more than one in eight were “completely free from knee pain at the end of the trial”, with the number being slightly higher among patients taking the lower dose.

Knee arthritis is a common condition, affecting about 20 percent of Americans over the age of 45. Northside Hospital of GeorgiaIt is more common in people with obesity,

Kenneth Custer, MD, executive vice president of Eli Lilly & Company and president of Lilly Cardiometabolic Health, said, “With seven additional Phase 3 readouts expected in 2026, we believe retretutide could become an important option for patients with significant weight loss needs and certain complications, including knee osteoarthritis.”

The drug was also found to eliminate knee pain in some patients.

The drug was also found to eliminate knee pain in some patients. ,getty images,

Eli Lilly said the drug also reduced known biomarkers of cardiovascular risk, and reduced systolic blood pressure, which is a measure of the force in your arteries as your heart beats, by 14 millimeters of mercury.

Additional results from the trial, which include a lower dose of four milligrams in addition to the nine and 12 milligrams and placebo tested in this trial, are expected next year.

Eli Lilly is together A new pill is being developed for weight loss And an amylin analog injection This will help people lose weight without causing muscle damage, which is a common side effect of current medications.

Uk